Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-3477

11 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-3477). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)

Image 1 (1638e85a 579b 4286 8f77 49f9e6c88488 01)
Chemical structure of Divalproex sodium, showing the molecular arrangement with sodium ions and the valproate component depicted in bracket notation representing the polymeric form.*
FDA Label Image

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)

Image 2 (1638e85a 579b 4286 8f77 49f9e6c88488 02)
A plot graph depicting the percentage reduction in CPS rate on the vertical axis versus the percentage of patients on the horizontal axis comparing Divalproex Sodium Delayed-Release (solid line) to placebo (dashed line). The graph shows patient improvement above the 0% line and worsening below, illustrating a trend of greater improvement with Divalproex Sodium compared to placebo.*
FDA Label Image

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)

Image 3 (1638e85a 579b 4286 8f77 49f9e6c88488 03)
A line graph comparing the percent reduction in CPS rate versus percent of patients for high dose and low dose Divalproex Sodium delayed release. The y-axis represents percent reduction in CPS rate ranging from -100% to 100%, while the x-axis shows percent of patients from 100% to 0%. Solid and dashed lines depict outcomes for high dose and low dose, respectively, indicating trends of improvement and worsening in CPS rate.*
FDA Label Image

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)

Image 4 (1638e85a 579b 4286 8f77 49f9e6c88488 04)
Bar chart comparing the effect of Placebo versus Divalproex Sodium Extended-Release Tablets, showing values of 0.6 for Placebo and 1.2 for Divalproex Sodium. The chart includes a notation indicating a statistical significance with p=0.006.*
FDA Label Image

Mm1 (Divalproex Sodium 500mg 70518 3477 00)

Mm1 (Divalproex Sodium 500mg 70518 3477 00)
Label for Divalproex Sodium Tablet Extended-Release 500 mg, oral dosage form, supplied as 30 tablets. The label shows the NDC number 70518-3477-00 and identifies the labeler as RemedyRepack Inc. Additional text notes repackaging details and storage instructions. Manufacturer information for Lupin Pharma, Baltimore, MD, is also included.*
FDA Label Image

Mm2 (Divalproex Sodium 500mg 70518 3477 01)

Mm2 (Divalproex Sodium 500mg 70518 3477 01)
Divalproex Sodium 500 mg extended-release tablet label showing a quantity of 30 tablets. The label includes the NDC number 70518-3477-01, with packaging and repackaging details by RemedyRepack Inc., Indiana, PA. It also lists the original manufacturer as Lupin Pharma, Baltimore, MD. The label contains storage instructions and a QR code.*
FDA Label Image

Mm3 (Divalproex Sodium 500mg 70518 3477 02)

Mm3 (Divalproex Sodium 500mg 70518 3477 02)
Label for Divalproex Sodium Tablet Extended-Release, 500 mg strength, with a quantity of 30 tablets. The label shows NDC number 70518-3477-02 and indicates the product is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer information lists Lupin Pharma, Baltimore, MD. Storage instructions and a QR code are also visible.*
FDA Label Image

Mm4 (Divalproex Sodium 500mg 70518 3477 03)

Mm4 (Divalproex Sodium 500mg 70518 3477 03)
Label for Divalproex Sodium Extended-Release Tablet 500 mg, containing 100 tablets per box. The label shows the NDC 70518-3477-03 and indicates it is repackaged by RemedyRepack Inc., Indiana, PA. It includes storage instructions and manufacturer information for Lupin Pharma, Baltimore, MD.*
FDA Label Image

Mm5 (Divalproex Sodium 500mg 70518 3477 04)

Mm5 (Divalproex Sodium 500mg 70518 3477 04)
Label for Divalproex Sodium extended-release tablet, 500 mg strength, in a package containing 1 tablet. The label includes the NDC number 70518-3477-04 and is repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer Lupin Pharma, Baltimore, MD is noted with an additional MFG NDC 68180-0261-02. Storage instructions and usual dosage directions to see insert are also present.*
FDA Label Image

Mm6 (Divalproex Sodium 500mg 70518 3477 05)

Mm6 (Divalproex Sodium 500mg 70518 3477 05)
Label for Divalproex Sodium extended-release tablets, 500 mg strength. The box contains 100 tablets. Labeler is RemedyRepack Inc., Indiana, PA. Manufacturer is Lupin Pharma, Baltimore, MD. The label includes storage instructions, usage notice, and states Rx only.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Divalproex Sodium 500 mg extended-release oral tablets, 30 count, repackaged by RemedyRepack Inc. The label includes directions to see the package insert and storage instructions. The original manufacturer is Lupin Pharma, Baltimore, MD.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.